Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cerilliant
US Department of Justice
Chinese Patent Office
Argus Health
Accenture
Colorcon
QuintilesIMS
Harvard Business School

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CALCITONIN-SALMON

« Back to Dashboard

Clinical Trials for Calcitonin-salmon

Trial ID Title Status Sponsor Phase Summary
NCT00004358 Phase II Study of Calcitonin for Tumoral Calcinosis Completed Ann & Robert H Lurie Children's Hospital of Chicago Phase 2 OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis. II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus. IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.
NCT00004358 Phase II Study of Calcitonin for Tumoral Calcinosis Completed National Center for Research Resources (NCRR) Phase 2 OBJECTIVES: I. Determine whether intermittent, long-term, subcutaneous administration of calcitonin increases phosphaturia, reduces hyperphosphatemia, and increases intact parathyroid hormone levels in patients with tumoral calcinosis. II. Determine whether calcitonin reduces or prevents tumor recurrence. III. Determine whether hyperphosphatemia abolishes the normal circadian pattern of serum phosphorus. IV. Determine how repetitive calcitonin administration alters the biochemical markers of bone metabolism in osteopenic patients with tumoral calcinosis.
NCT00239889 Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women Completed Novartis Phase 4 Calcitonin has been used for many years for treating osteoporosis in postmenopausal women, and it has been shown that calcitonin reduces pain after spine and hip fracture in women with osteoporosis. Therefore, this study assesses the safety and efficacy of salmon calcitonin nasal spray on muscle strength after a forearm fracture, pain, quality of life and fracture healing in postmenopausal women.
NCT00372099 Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women Completed Rene Rizzoli Phase 3 Calcitonin has been used for many years for treating osteoporosis in postmenopausal women. Recent data from the 2 years placebo-controlled QUEST study have shown a preservation of microarchitecture as measured by high resolution MRI in postmenopausal women with prevalent vertebral fractures at baseline.This pilot study should provide additional new insights in the mode of action of nasal calcitonin, on structural changes as measured by high resolution peripheral CT, and on the comparison between weight bearing and non weight bearing bones in postmenopausal women.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Calcitonin-salmon

Condition Name

Condition Name for Calcitonin-salmon
Intervention Trials
Osteoarthritis 4
Osteoporosis 3
Postmenopausal Osteoporosis 2
Osteoporosis, Postmenopausal 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Calcitonin-salmon
Intervention Trials
Osteoporosis 10
Osteoporosis, Postmenopausal 7
Osteoarthritis 4
Osteoarthritis, Knee 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Calcitonin-salmon

Trials by Country

Trials by Country for Calcitonin-salmon
Location Trials
United States 30
United Kingdom 7
Denmark 7
Poland 4
Romania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Calcitonin-salmon
Location Trials
Missouri 4
California 3
Wisconsin 2
Pennsylvania 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Calcitonin-salmon

Clinical Trial Phase

Clinical Trial Phase for Calcitonin-salmon
Clinical Trial Phase Trials
Phase 4 3
Phase 3 9
Phase 2 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Calcitonin-salmon
Clinical Trial Phase Trials
Completed 17
Terminated 2
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Calcitonin-salmon

Sponsor Name

Sponsor Name for Calcitonin-salmon
Sponsor Trials
Novartis 9
Eli Lilly and Company 4
Tarsa Therapeutics, Inc. 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Calcitonin-salmon
Sponsor Trials
Industry 21
Other 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Covington
Citi
QuintilesIMS
Cantor Fitzgerald
Healthtrust
UBS
Johnson and Johnson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.